Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd. operates as a clinical stage biotechnology company. It engages in the research and development of biotechnological and pharmaceutical products. The firm specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple Sclerosis, Crohn's disease and KRAS+ NSCLC. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. It specializes in developing transformative therapies for neurodegenerative and lung diseases. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

Tiziana Life Sciences PLC (NASDAQ:TLSA) said the US Food and Drug Administration (FDA) has given permission for the enrollment of additional Secondary Progressive Multiple Sclerosis (SPMS) patients for treatment with intranasal foralumab.  The company said its collaborators at the Brigham and Women's Hospital (BWH) Boston MA have received a 'Study May Proceed Letter' from the FDA to initiate treatment in up to an additional eight SPMS patients as part of an Intermediate-Size Patient Population Expanded Access Investigational New Drug (IND).

Tiziana Life Sciences receives FDA go-ahead to enroll more multiple sclerosis patients in expanded access program for treatment with intranasal foralumab

NEW YORK, April 05, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq:  TLSA ) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of monoclonal antibody delivery, today announced that its collaborators at the Brigham and Women's Hospital (BWH) Boston MA have received a ‘Study May Proceed Letter' from the U.S. Food and Drug Administration (FDA) permitting initiation of treatment in up to an additional eight SPMS patients as part of an Intermediate-Size Patient Population Expanded Access IND.

FDA Grants Permission to Enroll up to 8 Additional Secondary Progressive Multiple Sclerosis (SPMS) Patients in the Expanded Access Program with Intranasal Foralumab

NEW YORK, March 25, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of monoclonal antibody delivery, today announced initiation of a Phase 1b clinical trial to evaluate orally administered enteric-coated capsules of foralumab in patients with mild-to-moderate Crohn's Disease (CD). This revised protocol, as previously outlined in the Company's announcement on February 4, 2022, allows for the study of a broader patient population and a shorter dosing period. These protocol amendments or revisions are intended to expedite patient enrollment with study completion targeted for the fourth quarter of 2022.

Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn's Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, announces the availability of the replay of its March 14 KOL event entitled “Foralumab Clinical Update in Multiple Sclerosis” along with the slides from the presentation in the Investor Presentations section of its website (https://ir.tizianalifesciences.com/presentation). This morning, Zacks also published a research note to follow up on the KOL presentations and discussion on the positive clinical data after six months of treatment to a SPMS patient.

Tiziana Announces Availability of March 14 KOL Event Replay

Zak's Small Cap Research has provided its feedback from a ‘key opinion leader virtual event' hosted by Tiziana Life Sciences Ltd. The set-piece was organized after the publication of encouraging data from a trial of Tiziana's lead drug, which was used to treat a single patient with secondary progressive multiple sclerosis, an advanced form of the disease.

Tiziana Life Sciences: Analyst shares his feedback from key opinion leader call on Foralumab

Monday, March 14th @ 11 am ET, registration details below Monday, March 14th @ 11 am ET, registration details below

Tiziana Life Sciences Hosting Key Opinion Leader Virtual Event to Discuss the Intranasal Delivery of Foralumab in Multiple Sclerosis

Tiziana Life Sciences Ltd (NASDAQ: TLSA) has reported clinical data in a patient with Secondary Progressive Multiple Sclerosis (SPMS) following six months of treatment with intranasally administered foralumab. In addition to being well-tolerated, both biological and clinical.

Tiziana Life Shares Rise On Encouraging Data From Intranasal Foralumab In Multiple Sclerosis Patient

Agriforce Growing Systems Ltd

Heartcore Enterprises

Pintec Technology Holdings Ltd

Penny stocks are on the move today with some of the top companies in the space seeing major movement alongside heavy trading of their shares. The post Top Penny Stocks Today: Why PT, TLSA, AGRI and HTCR Are Up Thursday appeared first on InvestorPlace.

Top Penny Stocks Today: Why PT, TLSA, AGRI and HTCR Are Up Thursday

NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today reported positive clinical data in a patient with Secondary Progressive Multiple Sclerosis (SPMS), following completion of six months of treatment with intranasally administered foralumab, at the Brigham and Women's Hospital (BWH), Harvard University, Boston, MA. In addition to being well-tolerated, both biological and clinical improvements were seen in this patient using Tiziana's novel immunotherapy technology, which, importantly overcame the challenge of delivering this antibody across the blood-brain barrier to affect immunomodulation in the brain.

Tiziana Announces Positive Clinical Data from A Secondary Progressive Multiple Sclerosis Patient Treated for Six Months with Intranasally Administered Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody

NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.'s (Nasdaq: TLSA) former subsidiary, AccuStem Sciences, Inc. (OTC PINK: ACMSY) (formerly AccuStem Sciences Ltd.), today announced publication of new data in the European Journal of Cancer. Results demonstrate that StemPrintER is highly prognostic for risk of distant recurrence in women with breast cancer.

StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, announced today that Dr Kunwar Shailubhai, Chief Executive Officer and Chief Scientific Officer, will be presenting at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis in NYC on February 14-15 and virtually through the 17th.

Tiziana Life Sciences CEO to Present at Annual BIO CEO & Investor Conference

- Tiziana is Developing the First Oral Form of Foralumab in a Convenient Capsule to be Evaluated in Phase 1b Clinical Study

Tiziana Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Patients with Crohn's Disease

NEW YORK, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company developing breakthrough therapies for KRAS+ Non-Small Cell Lung Cancer (NSCLC) and transformational drug delivery technologies to enable alternative routes of immunotherapy, today announced its Chief Executive Officer and Chief Scientific Officer, Kunwar Shailubhai, Ph.D., will participate in a virtual fireside chat at the B.Riley Securities 2022 Oncology Conference on Thursday, 27 January 2022 at 4:00 p.m. EDT (U.S. and Canada) to provide Company updates.

Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Oncology Conference

NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that its Board of Directors has today authorized the Company's management to implement a stock repurchase program for up to $5 million of the Company's common shares at any time. The term of the board authorization is until December 31, 2022. The repurchase program may be suspended or discontinued at any time and will be funded using the Company's working capital.

Tiziana Life Sciences Ltd. To Implement Stock Repurchase Program for up to $5 Million

NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that Dr. Thomas Adams passed away on January 9, 2022. He served as a member of Tiziana Life Science's Board of Directors since February 2021.

Tiziana Life Sciences Announces Death of Director

Tiziana Life Sciences Ltd announced that the US Food and Drugs Administration (FDA) has accepted its request to enroll a second patient onto the ongoing clinical treatment of secondary progressive multiple sclerosis (SPMS). Tiziana, a biotechnology company that enables immunotherapies via novel routes of drug delivery, is evaluating nasally administered foralumab for SPMS.

Tiziana Life Sciences given nod for second patient to undergo multiple sclerosis treatment

- Clinical data from the first patient, after completing 3 out of 6 months, suggest that the treatment was well tolerated with a favorable clinical response

Tiziana Enrolls Second Patient in Ongoing Intranasal Foralumab Evaluation for Secondary Progressive Multiple Sclerosis

NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that senior management will present at the Biotech Showcase Conference and be available for one-on-one meetings throughout the conference. The conference is being held virtually from January 10th -12th and also during January 17th -19th.

Tiziana Life Sciences to Participate in 2022 Biotech Showcase Virtual Investor Conference

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Share Capital Consolidation and Commencement of trading in the New Tiziana Shares on NASDAQ

Tiziana Life Sciences - Scheme Effective Date

LONDON and NEW YORK, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 60,000 ordinary shares of 3p each in the market at a price of 55p per share.

Tiziana Life Sciences plc: PDMR Dealing

LONDON and NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("Old Tiziana") a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases announced on 20 August 2021 that it had formally commenced its strategic plan to change its corporate structure by establishing Tiziana Life Sciences Ltd (“New Tiziana”), a Bermuda-incorporated company, as the ultimate parent company of the Tiziana Group. The reorganisation will be achieved by a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme").

Tiziana Life Sciences plc: Court Sanctions the Scheme of Arrangement and approves Reduction of Capital

LONDON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- On 20 August 2021, Tiziana Life Sciences Plc (“Old Tiziana”) announced that it has formally commenced its strategic plan to change its corporate structure by establishing Tiziana Life Sciences Ltd (“New Tiziana”), a Bermuda-incorporated company, as the ultimate parent company of the of the Tiziana Group, to be effected by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the “Scheme”).

Tiziana Life Sciences Plc - Results of Court Meeting and General Meeting

Interim results from Tiziana Life Sciences PLC (NASDAQ:TLSA, LSE:TILS, FRA:RTRA, OTC:TIZAF) revealed the significant progress made by the drug developer in the first half of the year. In the six-month period to 30 June, the group was able to provide the first early demonstration that its monoclonal antibody (mAB) treatment, Foralumab, could be administered nasally using the local and lymphatic immune systems directly.

Tiziana Life Sciences' half-term report reveals it has made progress on all fronts

Interim results from Tiziana Life Sciences PLC revealed the significant progress made by the drug developer in the first six months of the year. In six month period to June 30, the group was able to provide the first early demonstration that its monoclonal antibody (mAB) treatment, Foralumab, could be administered nasally using the local and lymphatic immune systems directly.

News for Tiziana Life Sciences Ltd Stock (TLSA)